Home > Research Areas > Cancer > Liver Cancer
Cat. No. Product name CAS No.
DC10372 Amcasertib(BBI503) Featured

Amcasertib(BBI503) is an orally administered investigational agent designed to inhibit cancer stem cell pathways, including Nanog, by targeting stemness kinases.

1129403-56-0
DC11163 AST-3424

AST-3424 (OBI-3424, TH-3424) is a first-in-class, novel prodrug that selectively targets cancers overexpressing the enzyme AKR1C3, OBI-3424 is a highly selective prodrug that is converted by AKR1C3 to a DNA alkylating agent.

2097713-68-1
DC5032 AZD1480

AZD1480 is a novel ATP-competitive JAK2 inhibitor with IC50 of 0.26 nM, selectivity against JAK3 and Tyk2, and to a smaller extent against JAK1. Phase 1/2.

935666-88-9
DC11295 AZD-4573

AZD4573 is a CDK9 inhibitor with an IC50 of <3 nM extracted from patent US 20160376287 A1, example 14.

2057509-72-3
DC10092 BLU554(Fisogatinib) Featured

BLU-554 is a potent fibroblast growth factor receptor 4 (FGFR4) inhibitor.

1707289-21-1
DC2019 Brivanib (bms-540215) Featured

Brivanib is an ATP-competitive inhibitor against human VEGFR2 and FGFR with IC50 of 25 nM and 148 nM, respectively.

649735-46-6
DC10440 CF-102(2-Cl-IB-MECA) Featured

CF-102(2-Cl-IB-MECA) is a selective A3 adenosine receptor agonist (Ki = 0.33 nM). Displays 2500- and 1400-fold selectivity over A1 and A2A receptors respectively. target: A3 adenosine receptor agonist;

163042-96-4
DC10559 Derazantinib (ARQ 087)

Derazantinib (Derazantinib) is an ATP competitive tyrosine kinase inhibitor; exhibits potent activity against FGFR1-3 chondrocytes with IC50s of 4.5, 1.8, and 4.5 nM, respectively.

1234356-69-4
DC5065 Golvatinib (E7050) Featured

E-7050 is hepatocyte growth factor receptors (HGFR).

928037-13-2
DCAPI1441 Seocalcitol

EB1089 is an analog of 1,25 dihydroxyvitamin D which acts as a vitamin D receptor (VDR). EB1089 is noted to reverse hypercalcemia and is a potent inhibitor of PTH-rP (parathyroid hormone-related peptide, PTHRP) in vitro. In studies utilizing a squamous ca

134404-52-7
DC7408 Tepotinib(EMD-1214063) Featured

EMD 1214063 is a potent and selective c-Met inhibitor with IC50 of 4 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer.

1100598-32-0
DC10128 FGF401

FGF401 is an inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity.

1708971-55-4
DC11086 Foslinanib

Foslinanib (TRX-818) is an orally bioavailable agent with potential antineoplastic and anti-vasculogenic mimicry (VM) activities, induces cancer cell apoptosis and inhibits cancer cell proliferation.

1256037-60-1
DC10033 H3B-6527 Featured

H3B-6527 is an orally bioavailable inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity.

1702259-66-2
DC4105 Linsitinib(OSI-906) Featured

OSI-906 (Linsitinib) is a selective inhibitor of IGF-1R and IR with IC50 of 35 nM and 75 nM, respectively.

867160-71-2
DC7808 Refametinib (BAY86-9766) Featured

Refametinib (RDEA119, Bay 86-9766) is a potent, ATP non-competitive and highly selective inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively.

923032-37-5
DC7261 Resminostat hydrochloride (4SC-201)

Resminostat(RAS2410; 4SC-201) is a potent inhibitor of HDAC1/3/6(IC50=43-72 nM); less potent to HDAC8 with IC50 of 877 nM.

1187075-34-8
DC11812 SF-1126

SF-1126 is a pan PI3K/BRD4 inhibitor, RGDS-conjugated LY294002 prodrug that exhibits increased solubility and binds to specific integrins.

936487-67-1
DC7065 Tivantinib (ARQ 197) Featured

Tivantinib (ARQ 197) is the first non-ATP-competitive c-Met inhibitor with Ki of 0.355 μM, little activity to Ron, and no inhibition to EGFR, InsR, PDGFRα or FGFR1/4.

905854-02-6
DC11087 TRX-818 sodium

TRX-818 sodium (Foslinanib sodium ) is an orally bioavailable agent with potential antineoplastic and anti-vasculogenic mimicry (VM) activities, induces cancer cell apoptosis and inhibits cancer cell proliferation.

1256037-62-3
Page 1 / Total 1 FirstPrevNextLastGoto